Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called “incretin-based therapies” (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome trials (CVOTs) have provided useful information that has helped to shape changes in clini cal practice guidelines for the management of T2DM. At the same time, the mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of these medications are still being explored.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi, Manfredi Rizzo Source Type: research
More News: Biomedical Science | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Incretin Therapy